Kura Oncology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 142
- Market Cap
- $1.5B
- Website
- http://www.kuraoncology.com
- Introduction
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors...
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
Kura Oncology appoints Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience and leadership. He is currently a Senior Advisor at Frazier Healthcare Partners and has held senior roles at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, and Genzyme Corporation. Dr. Vasconcelles expressed enthusiasm for Kura's precision oncology approach and its menin inhibitor program for acute leukemias.
Kura Oncology, Inc. Latest Stock News & Market Updates
Kura Oncology (KURA) is a clinical-stage biopharmaceutical company developing precision medicines for cancer, with key candidates like Tipifarnib, Ziftomenib, and KO-2806. Recent achievements include preliminary data from the KOMET-007 trial and securing financing through 2027.
© Copyright 2024. All Rights Reserved by MedPath